Aspirin not associated with decreased prostate cancer-associated mortality
the ONA take:
According to a recent study published in The Journal of Urology, researchers from Jewish General Hospital in Montreal, Quebec, Canada, have found that aspirin use does not decrease the risk of mortality associated with prostate cancer.
For the study, researchers followed a cohort of 11,779 men diagnosed with nonmetastatic prostate cancer between 1998 and 2009. Patients were followed until 2012 in order to assess associations between aspirin use and both prostate and all-cause mortality.
Results showed that a median follow-up of 5.4 years, aspirin use after cancer diagnosis was associated with increased risks of prostate cancer mortality (HR = 1.46; 95% CI: 1.26-1.50).
Researchers also found that the risk of prostate cancer-associated mortality was increased in patients who started using aspirin after they were were diagnosed with cancer (HR = 1.84; 95% CI: 1.59-2.12), whereas those who were using aspirin before diagnosis did not have an increased risk of cancer-associated mortality (HR = 0.97; 95% CI: 0.81-1.16.
The study showed similar risks for all cause-mortality and post- and pre-diagnostic aspirin use.
Aspirin use does not decrease the risk of mortality associated with prostate cancer.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Mammograms (Fact Sheet)
- Shifts in Cancer Burden for People With HIV Projected
- Tissue Biobank Procurement Consent Should Include Discussion of Confidentiality Risks
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|